Kiniksa Pharmaceuticals International, plc (KNSA)

KNSA Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	175.68	165.6	183.58	107.95	122.72	122.47
Short-Term Investments	350.25	248.48	60.05	98.42	67.89	59.73
Cash & Short-Term Investments	525.93	414.07	243.63	206.37	190.61	182.2
Cash Growth	70.88%	69.96%	18.05%	8.27%	4.61%	-43.68%
Receivables	23.49	15.59	41.72	21.27	20.32	3.99
Inventory	70.93	54.9	26.36	31.12	21.6	3.68
Prepaid Expenses	48.29	42.61	20.08	17.54	10.54	6.59
Total Current Assets	668.63	527.18	331.8	276.3	243.06	196.45
Property, Plant & Equipment	10.93	11.75	11.04	12.67	7.04	8.38
Other Intangible Assets	14.75	15.25	16.25	17.25	18.25	19.25
Long-Term Deferred Tax Assets	190.97	198.15	211.15	219.28	185.5	-
Other Long-Term Assets	10.83	11.31	10.32	0.83	5.82	8.72
Total Assets	896.11	763.63	580.55	526.32	459.67	232.8

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	12.4	2.03	2.04	8.25	7.9	1.87
Accrued Expenses	134.78	112.04	80.51	44.67	30.11	38.03
Current Portion of Leases	4.01	2.99	1.99	2.25	3.3	3.38
Current Unearned Revenue	-	-	-	0.31	-	-
Other Current Liabilities	20.05	22.13	16.08	8.19	5.75	1.54
Total Current Liabilities	171.25	139.18	100.62	63.67	47.07	44.82
Long-Term Leases	4.89	6.51	7.86	10.01	2.62	2.67
Long-Term Unearned Revenue	31.81	31.81	31.81	11.95	12	-
Other Long-Term Liabilities	34.02	18.52	1.82	1.86	1.84	0.27
Total Liabilities	241.96	196.03	142.12	87.48	63.52	47.76

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	1,070	1,030	959.72	916.76	888.12	860.48
Retained Earnings	-414.11	-462.14	-521.14	-477.95	-492.03	-675.4
Comprehensive Income & Other	-1.38	-0.03	-0.16	0.01	0.04	-0.07
Total Common Equity	654.15	567.61	438.44	438.84	396.15	185.04
Shareholders' Equity	654.15	567.61	438.44	438.84	396.15	185.04
Total Liabilities & Equity	896.11	763.63	580.55	526.32	459.67	232.8

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	8.9	9.5	9.86	12.26	5.92	6.05
Net Cash (Debt)	517.03	404.58	233.77	194.11	184.69	176.15
Net Cash Growth	73.49%	73.06%	20.43%	5.10%	4.85%	-44.34%
Net Cash Per Share	6.31	5.12	3.27	2.70	2.62	2.57
Filing Date Shares Outstanding	78.02	76.54	72.64	70.62	69.75	69.1
Total Common Shares Outstanding	77.98	76.29	72.52	70.46	69.7	69.06
Working Capital	497.39	387.99	231.18	212.63	195.99	151.62
Book Value Per Share	8.39	7.44	6.05	6.23	5.68	2.68
Tangible Book Value	639.4	552.36	422.19	421.59	377.9	165.79
Tangible Book Value Per Share	8.20	7.24	5.82	5.98	5.42	2.40
Machinery	4.53	4.28	4.77	4.58	4.59	4.65
Construction In Progress	0.75	0.26	0.16	0.01	-	0.17
Leasehold Improvements	4.83	4.64	3.93	3.93	3.93	3.93

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jul 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 26, 2026

Data Sources Report a data error